As the generic market for Visanne, Bayer's endometriosis treatment, is growing rapidly, the status of the original drug is being threatened. According to the pharmaceutical industry, as the number of patients with endometriosis increased significantly, the treatment market was also found to be growing significantly.

Looking at the health insurance treatment status of 'endometriosis (N80)' from 2016 to 2020 announced by the NHIS, the number of endometriosis patients increased by 48.2% from 104,689 in 2016 to 155,183 in 2020. Due to this influence, medical expenses also increased by 79.6% from 56.6 billion won in 2016 to 101.6 billion won in 2020, and outpatient medical expenses surged 147.7% from 16.4 b